Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Gross Margin (2017 - 2025)

Aclaris Therapeutics has reported Gross Margin over the past 9 years, most recently at 58.92% for Q4 2025.

  • Quarterly results put Gross Margin at 58.92% for Q4 2025, down 3343.0% from a year ago — trailing twelve months through Dec 2025 was 73.28% (down 1180.0% YoY), and the annual figure for FY2025 was 73.28%, down 1180.0%.
  • Gross Margin for Q4 2025 was 58.92% at Aclaris Therapeutics, down from 83.69% in the prior quarter.
  • Over the last five years, Gross Margin for ACRS hit a ceiling of 95.87% in Q4 2023 and a floor of 20.51% in Q1 2022.
  • Median Gross Margin over the past 5 years was 67.15% (2024), compared with a mean of 62.68%.
  • Biggest five-year swings in Gross Margin: surged 6524bps in 2022 and later plummeted -3343bps in 2025.
  • Aclaris Therapeutics' Gross Margin stood at 23.45% in 2021, then skyrocketed by 278bps to 88.69% in 2022, then rose by 8bps to 95.87% in 2023, then fell by -4bps to 92.35% in 2024, then crashed by -36bps to 58.92% in 2025.
  • The last three reported values for Gross Margin were 58.92% (Q4 2025), 83.69% (Q3 2025), and 71.02% (Q2 2025) per Business Quant data.